Back

The impact of GLP-1 receptor agonists on cognitive decline in heart failure patients: a retrospective cohort study using real world data

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Optimising care of comorbidities in heart failure Comorbidities ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Andreas Kalogeropoulos

Stony Brook University, Stony Brook (United States of America)

6 More presentations in this session

Presentation thumbnail
Associations between rapid renal function decline and prior cardiovascular events in patients with heart failure and preserved ejection fraction: insights from the PURSUIT-HFpEF registry
Doctor M. Okada (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Predictors and prognostic impact of chronic kidney disease in hospitalized patients with heart failure - insights from the cardiomining study
Doctor K. Barmpagiannos (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Hyperkalaemia in patients with heart failure in German general practices: prevalence, diagnosis and treatment: The WATCH-K study
Professor I. Eitel (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics, prescribing patterns and outcomes in individuals with heart failure and type 1 diabetes versus type 2 diabetes
Doctor Y. Liew (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Low serum iron and transferrin saturation are associated with new-onset heart failure
Doctor C. Cabrera (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Optimising care of comorbidities in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Role of oral semaglutide therapy on incidence of cognitive impairment in a cohort of elderly diabetics with Heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Newer GLP-1 receptor agonists and clinical outcomes in heart failure with reduced ejection fraction: a real-world comparative study
thumbnail
Congress Presentation
Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources